摘要
目的 探讨丝氨酸蛋白酶Omi/HtrA2在胃癌组织中的表达及其与胃癌临床病理特征及预后的关系.方法 采用免疫组化法检测68例胃癌组织、15例癌旁组织及15例正常胃黏膜组织中Omi/HtrA2的表达,并分析其表达与胃癌临床病理特征及预后的关系.结果 Omi/HtrA2在胃癌组织中的阳性表达率为73.5%（50/68）,高于癌旁组织（13.3%,2/15）和正常胃黏膜（6.7%,1/15）,差异有统计学意义（P＜0.05）.胃癌组织中Omi/HtrA2的表达与患者的性别、年龄、肿瘤大小及浸润深度无关（P＞0.05） 与肿瘤的分化程度、淋巴结转移和临床分期有关（P＜0.05）.本组胃癌患者5年总体生存率为63.3%,其中Omi/HtrA2表达阳性组和阴性组分别为72.0%和61.1%,两组比较,差异并无统计学意义（P＞0.05）.结论 Omi/HtrA2在胃癌组织中高表达,其表达与胃癌分化程度、淋巴结转移及TNM分期有关,但并不影响胃癌患者的预后.
Objective To explore the expression of serine protease Omi/HtrA2 in gastric carcinoma tissue and its association with clinicopathological features and prognosis. Methods Omi/HtrA2 protein expression levels were detected by immunohistochemistry method in resected gastric carcinomas（n=68）, adjacent noncancerous tissues（n=15）, and normal tissues（n=15）, and its association with clinicopathological features and prognosis were analyzed. Results Omi/HtrA2 expression was positive in 73.5%（50/68） of gastric cancer tissues, which was significantly higher than that in adjacent noncancerous tissues and normal tissues（P〈0.05）. There were no significant differences in Omi/HtrA2 expression with respect to sex, age, tumor size, and depth of invasion（all P〉0.05）. Omi/HtrA2 expression level was significantly associated with tumor differentiation, extent of lymph node metastasis, and tumor stage（all P〈0.05）. Overall 5-year survival rate of patients with gastric carcinoma was 63.3%. Five-year survival rate was higher in Omi/HtrA2 positive cases than Omi/HtrA2 negative cases（72.0% vs. 61.1%）, however the difference was not statistically significant. Conclusions Omi/HtrA2 expression is more common in gastric carcinoma. Omi/HtrA2 expression is associated with tumor differentiation, extent of lymph node metastasis, and tumor stage.
出处
《中华胃肠外科杂志》
CAS
北大核心
2010年第10期766-769,共4页
Chinese Journal of Gastrointestinal Surgery
基金
基金项目：广东省科技计划项目（20098030801144）
